There is a lot of excitement surrounding the potential of stem cells to treat COVID-19.
Stem cells can regenerate tissue and boost immunity, which could help treat acute respiratory distress syndrome (ARDS), pulmonary inflammation, and edema.
So far, animal studies have yielded promising results using stem cells to treat ARDS. For example, one study showed that treatment with mesenchymal stem cells reduced lung injury and improved survival in mice with ARDS.
Stem cells can regenerate tissue and boost immunity, potentially treating acute respiratory distress syndrome (ARDS), pulmonary inflammation, and edema. Animal studies show promising results, with mesenchymal stem cells (MSCs) reducing lung injury and improving survival in mice with ARDS. MSCs are notable for inhibiting inflammation caused by COVID-19-induced cytokine storms. A recent human clinical trial involving MSCs highlighted their potential benefits, though further studies are needed to confirm their efficacy in treating COVID-19.